News Release on Preliminary Data Using Oncotype DX® in DCIS

A recent news release from Genomic Health, Inc. indicates preliminary data shows that the Oncotype DX® test can provide a score predicting risk of local recurrence in patients with a diagnosis of ductal carcinoma in situ (DCIS).

DCIS is a very heterogeneous disease and there is disagreement in the breast care community as to how to treat certain types of DCIS and do all types require post-excision radiation therapy? In fact, some in the breast care community do not like using the term “carcinoma” for a low grade in situ process (which can be confused with ADH).

The data in the literature has been conflicting regarding whether some patients with small areas of low grade DCIS need post-excision radiation therapy vs. other patients with larger foci, or higher grade, DCIS.  I look forward to the release of the finalized data from Genomic Health, Inc. and the Eastern Cooperative Oncology Group (EGOG) at this year’s San Antonio Breast Cancer Symposium.

Disclosure:  I am not currently or have never been an employee or consultant for Genomic Health, Inc.

© 2011 Seattle Breast Pathology Consultants, LLC. All rights reserved.

Leave a Reply